| scholarly article | Q13442814 |
| P50 | author | Brian Druker | Q373427 |
| Nick Holford | Q51935521 | ||
| Michael A Caligiuri | Q97333782 | ||
| Michael C. Heinrich | Q40526741 | ||
| P2093 | author name string | Stephen D Nimer | |
| Richard M Stone | |||
| Michael R Cooper | |||
| Daniel J DeAngelo | |||
| Jean-Michel Lecerf | |||
| Mark L Heaney | |||
| Michael D Karol | |||
| Peter T Curtin | |||
| Rebecca B Klisovic | |||
| Ronald L Paquette | |||
| Shihong Sheng | |||
| P2860 | cites work | Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. | Q46608658 |
| Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. | Q54704480 | ||
| Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene | Q73674699 | ||
| Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia | Q77363619 | ||
| Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients | Q81923865 | ||
| Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 | ||
| Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. | Q27824774 | ||
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease | Q39218023 | ||
| Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. | Q40534979 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia | Q43665962 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. | Q43977683 | ||
| CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). | Q44068434 | ||
| Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family | Q44093551 | ||
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia | Q44611047 | ||
| Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Q45042550 | ||
| FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model | Q45271875 | ||
| Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis | Q46549470 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| leukemia | Q29496 | ||
| pharmacodynamics | Q725307 | ||
| myelodysplastic syndrome | Q954625 | ||
| P304 | page(s) | 3674-3681 | |
| P577 | publication date | 2006-08-10 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics | |
| P478 | volume | 108 |
| Q33913465 | A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma |
| Q42192063 | A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response |
| Q41973517 | A potential therapeutic target for FLT3-ITD AML: PIM1 kinase |
| Q39166725 | A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. |
| Q37312735 | ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside |
| Q37373040 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) |
| Q27852087 | Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD |
| Q37840260 | Acute myeloid leukaemia in the elderly: a review |
| Q38168893 | Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. |
| Q37129915 | Antiangiogenic therapy in brain tumors |
| Q37724957 | Bench to bedside targeting of FLT3 in acute leukemia |
| Q41549311 | Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase |
| Q28301344 | Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review |
| Q58558233 | Clinical use of FLT3 inhibitors in acute myeloid leukemia |
| Q42729095 | Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation |
| Q35560182 | Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors |
| Q37083261 | Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis |
| Q33749036 | Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. |
| Q49207324 | Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. |
| Q40165118 | Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. |
| Q35003666 | Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics |
| Q41071486 | Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth |
| Q36293678 | Effects of Toll-like receptor signals in T-cell neoplasms |
| Q34004131 | Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia |
| Q37670417 | Exploiting cellular pathways to develop new treatment strategies for AML. |
| Q37039628 | Exploiting signal transduction pathways in acute myelogenous leukemia |
| Q38675400 | FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions |
| Q39513601 | FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations |
| Q38026453 | FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia |
| Q38101284 | FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance |
| Q79609943 | FLT3 inhibitors for the treatment of autoimmune disease |
| Q38200564 | FLT3 inhibitors in AML: are we there yet? |
| Q37810061 | FLT3 inhibitors in acute myeloid leukemia |
| Q59793942 | FLT3 inhibitors in acute myeloid leukemia |
| Q37829880 | FLT3 inhibitors: a story of the old and the new. |
| Q28289859 | FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations |
| Q34350591 | FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes |
| Q37842585 | FMS-like tyrosine kinase 3 inhibitors: a patent review |
| Q48497112 | Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. |
| Q58598813 | Functional genomic landscape of acute myeloid leukaemia |
| Q59086861 | Functional genomic landscape of acute myeloid leukaemia |
| Q36964688 | Future options for imatinib mesilate-resistant tumors |
| Q37785197 | Gamma-secretase and the intramembrane proteolysis of Notch |
| Q33391513 | Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor |
| Q37406963 | Genomic approaches to small molecule discovery |
| Q90623570 | Gilteritinib: potent targeting of FLT3 mutations in AML |
| Q36591388 | High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia |
| Q34573775 | Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q34591403 | Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens |
| Q37810104 | Lestaurtinib: a multi-targeted FLT3 inhibitor |
| Q37375423 | Mechanisms of resistance to FLT3 inhibitors. |
| Q35914782 | Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers |
| Q47727992 | Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis |
| Q37183513 | Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia |
| Q37260555 | Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents |
| Q38357132 | Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. |
| Q64099168 | Network-based prediction of drug combinations |
| Q34555328 | Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome |
| Q84122235 | New agents for the treatment of patients with acute lymphoblastic leukemia |
| Q36137696 | Notch signaling in developmental and tumor angiogenesis |
| Q64987877 | Novel Thienopyrimidine Derivative, RP-010, Induces β-Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells. |
| Q42721533 | Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse |
| Q89771836 | Overview of Basic Mechanisms of Notch Signaling in Development and Disease |
| Q41245849 | Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns. |
| Q37627876 | Pharmacogenomics in acute myeloid leukemia. |
| Q36907832 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation |
| Q34095013 | Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia |
| Q33986236 | Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia |
| Q40289674 | Precision Subtypes of T Cell-Mediated Rejection Identified by Molecular Profiles |
| Q54335286 | Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. |
| Q36929806 | Progress in the treatment of acute myeloid leukemia |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q38241988 | Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia |
| Q91861935 | Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 |
| Q38720331 | RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia. |
| Q90166734 | Recent drug approvals for acute myeloid leukemia |
| Q37567632 | Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia |
| Q39016415 | Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies |
| Q24337247 | SYK is a critical regulator of FLT3 in acute myeloid leukemia |
| Q39769534 | Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis |
| Q34158454 | Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies |
| Q43169281 | Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3. |
| Q39176288 | Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). |
| Q46815326 | Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. |
| Q35750567 | Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions |
| Q36129030 | Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. |
| Q48278191 | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
| Q37257308 | Targeting FLT3 for the treatment of leukemia |
| Q35865681 | Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies |
| Q58555667 | Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance |
| Q38011962 | Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia |
| Q36410157 | Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. |
| Q47445868 | The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q37927089 | The clinical development of FLT3 inhibitors in acute myeloid leukemia |
| Q39302268 | The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia |
| Q38144189 | The role of quizartinib in the treatment of acute myeloid leukemia |
| Q34636735 | Treatment of FLT3-ITD acute myeloid leukemia. |
| Q37899785 | Treatment of acute lymphoblastic leukemia in adolescents and young adults |
| Q36977560 | Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant |
| Q34104338 | UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor |
| Q38182335 | Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? |
| Q27853031 | Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Le |
Search more.